In 2015, DNDi launched the Chagas Access Project to increase access to diagnosis and treatment for Chagas disease. Working in collaboration with local, regional, and national partners in several endemic countries, DNDi has launched a series of projects to pilot new models of patient-centred care with a test-and-treat approach. 

The new patient-centred approach was first implemented in Colombia in collaboration with the Ministry of Health and Social Protection (MSPS), the Colombian National Health Institute (INS), and other partners working together to support the implementation of a comprehensive roadmap for Chagas care. In seven Colombian departments where Chagas disease is highly endemic, the projects have increased access to testing and treatment by training healthcare staff on the most up-to-date treatment guidelines; simplifying and accelerating the procedure for diagnosis; and decentralizing treatment so that it would be available closer to where patients live. The same model is being implemented in Guatemala in three of ten endemic areas of the country.

The collaborative work carried out by the Colombian MSPS, local health systems, and DNDi in the project areas produced robust results. When comparing access to care for Chagas disease before and after implementation of the pilot projects, several improvements were made:

  • The average number of people tested annually increased nearly five-fold, from 426 before the project to 2427 after its implementation
  • The average number of cases of Chagas disease detected per year increased from 37 to 262, meaning more people could receive timely care
  • Average wait times for confirmation of diagnosis decreased by over 90%, from 258 to 19 days
  • Average wait times between confirmed diagnosis and start of treatment decreased by over 60%, from 354 days to 135

In the United States, DNDi started working with the Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center in Los Angeles to identify the main barriers to treatment access and promote of testing and treatment. Through the project, the first large-scale prevalence study on Chagas disease in a major US city was published, describing findings from the Center’s community screening programme in Los Angeles. DNDi is part of the US Chagas Network, which actively collaborates to improve access to healthcare for people living with Chagas disease and to promote research and development for new treatments for the disease.

Project updates

DNDi teams and partners made significant progress in evaluating the performance of the rapid diagnostic test in Colombia, Guatemala, and Argentina, with pilot use and implementation of the test beginning in the three countries.

In Colombia and Guatemala, monitoring and evaluation efforts continued and activities to promote access to treatment were strengthened. In Colombia, our teams and partners conducted comparative analyses of Chagas treatment gaps and continued training programmes on clinical management of Chagas.

A study to assess the acceptability of contraception among women receiving treatment for Chagas in clinical trials – and in standard treatment settings – was initiated in Brazil and Colombia. In Guatemala and Colombia, the project advanced in its work to incorporate intercultural care routes into standard Chagas treatment, with a specific focus on the worldviews of indigenous peoples.

Chagas Access: The pilot experience in Colombia
2021

English
Español
Português

Screenshot of the Science Explained on Improving access to testing for Chagas disease in Colombia

Improving access to testing for Chagas disease in Colombia
2019

English
Español

Ending the neglect of Chagas in Colombia

Bringing Chagas disease care to a remote Colombian region